LEADER 05982nam 2201753z- 450 001 9910372785603321 005 20231214133526.0 010 $a3-03921-849-2 035 $a(CKB)4100000010163770 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/61237 035 $a(EXLCZ)994100000010163770 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTransmucosal Absorption Enhancers in the Drug Delivery Field 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (406 p.) 311 $a3-03921-848-4 330 $aDevelopment of strategies to assist the movement of poorly permeable molecules across biological barriers has long been the goal of drug delivery science. In the last three decades, there has been an exponential increase in advanced drug delivery systems that aim to address this issue. However, most proprietary delivery technologies that have progressed to clinical development are based on permeation enhancers (PEs) that have a history of safe use in man. This Special Issue entitled ?Transmucosal Absorption Enhancers in the Drug Delivery Field? aims to present the current state-of-the-art in the application of PEs to improve drug absorption. Emphasis is placed on identification of novel permeation enhancers, mechanisms of barrier alteration, physicochemical properties of PEs that contribute to optimal enhancement action, new delivery models to assess PEs, studies assessing safety of PEs, approaches to assist translation of PEs into effective oral, nasal, ocular and vaginal dosage forms and combining PEs with other delivery strategies. 610 $achitosan 610 $aintestinal epithelial cells 610 $aocular delivery 610 $aamphiphilic polymers 610 $acornea 610 $atight junction modulator 610 $acyclodextrin 610 $apermeability 610 $agemini surfactant 610 $atransferrin 610 $acompound 48/80 610 $aepithelial permeability 610 $acervicovaginal tumors 610 $ananoparticles 610 $aconfocal laser scanning microscopy 610 $asafety 610 $aformulation 610 $asalcaprozate sodium 610 $aintestinal absorption 610 $aFITC-dextran 610 $acurcumin 610 $ablock copolymers 610 $anasal vaccination 610 $awhole leaf 610 $abrush border 610 $aocular drug delivery 610 $avaccine adjuvant 610 $ananoparticle 610 $anasal delivery 610 $aefflux 610 $apermeation enhancers 610 $aabsorption enhancers 610 $anose to brain delivery 610 $asmall intestine 610 $aepithelium 610 $aCNS disorders 610 $aabsorption modifying excipients 610 $ainsulin 610 $aabsorption enhancer 610 $agel 610 $aintestinal delivery 610 $athermogel system 610 $aCaco-2 610 $abiocompatibility studies 610 $aabsorption enhancement 610 $aman 610 $aPN159 610 $apoorly absorbed drug 610 $atryptophan 610 $atight junction 610 $aoral macromolecule delivery 610 $apenetration enhancer 610 $aintestinal permeation enhancers 610 $ananocrystals 610 $asimvastatin 610 $ananomedicine 610 $aenterocyte 610 $aN-dodecyl-?-D-maltoside (DDM) 610 $acell-penetrating peptide 610 $aquaternization 610 $aKLAL 610 $anasal 610 $anasal permeability 610 $atransmucosal drug delivery 610 $aCaco-2 cells 610 $amast cell activator 610 $apenetration enhancers 610 $adrug delivery 610 $anose-to-brain 610 $abioenhancer 610 $apolymeric micelles 610 $amucoadhesion 610 $acell-penetrating peptide (CPP) 610 $asimulated intestinal fluid 610 $avaginal delivery 610 $anasal formulation 610 $apharmacokinetic interaction 610 $asodium caprate 610 $aclinical trial 610 $atransmucosal permeation 610 $adrug absorption enhancer 610 $asugar-based surfactants 610 $ananocapsules 610 $aimatinib 610 $ateriparatide 610 $aosteoporosis 610 $ahydrophobization 610 $aF-actin 610 $acombined microsphere 610 $atransepithelial electrical resistance 610 $aoral delivery 610 $aocular conditions 610 $ametabolism 610 $aantimicrobial peptide 610 $apermeation enhancer 610 $adrug administration 610 $aantiepileptic drug 610 $aamino acid 610 $ain vivo studies 610 $asodium cholate (NaC) 610 $aepithelial transport 610 $apreclinical 610 $anose to brain transport 610 $apharmacokinetics 610 $achitosan derivatives 610 $aophthalmology 610 $atight junctions 610 $asheep 610 $acationic functionalization 610 $aGLP-1 610 $apulmonary 610 $aand liposome 610 $acytochrome P450 610 $aclaudin 610 $aP-glycoprotein 610 $ain situ hydrogel 610 $amucoadhesiveness 610 $aPTH 1-34 610 $aAloe vera 610 $aoral peptides 700 $aMaher$b Sam$4auth$01322342 702 $aIllum$b Lisbeth$4auth 702 $aCasettari$b Luca$4auth 906 $aBOOK 912 $a9910372785603321 996 $aTransmucosal Absorption Enhancers in the Drug Delivery Field$93034888 997 $aUNINA